Can a common diabetes drug help fight aggressive brain tumors?
NCT ID NCT07541781
First seen May 01, 2026 · Last updated May 01, 2026
Summary
This early-phase trial tests whether sitagliptin, a diabetes medicine, can boost the immune system to fight recurrent grade 4 gliomas (a fast-growing brain cancer). About 45 adults whose cancer has returned after standard treatment will receive sitagliptin combined with bevacizumab. The study aims to find the safest dose and see if the drug reduces certain immune cells that help tumors hide.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Iowa Health Care
Iowa City, Iowa, 52242, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.